Ocugen Toekomstige groei
Future criteriumcontroles 2/6
Ocugen is forecast to grow earnings and revenue by 47.7% and 69.5% per annum respectively while EPS is expected to grow by 50.8% per annum.
Belangrijke informatie
47.7%
Groei van de winst
50.8%
Groei van de winst per aandeel
| Biotechs winstgroei | 27.1% |
| Inkomstengroei | 69.5% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 15 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Ocugen announces peer-reviewed publication on COVID-19 vaccine
Sep 14Ocugen initiated with Buy at Mizuho citing favorable setup ahead of key readout
Aug 23Ocugen Q2 2022 Earnings Preview
Aug 04Ocugen: A First Take
Jul 18Ocugen in renewed focus as FDA wants COVID boosters to fight Omicron variant
Jul 05Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 10 | -62 | -78 | N/A | 2 |
| 12/31/2025 | N/A | -60 | -70 | N/A | 4 |
| 12/31/2024 | 3 | -58 | -68 | N/A | 4 |
| 6/30/2024 | 7 | -45 | -54 | -46 | N/A |
| 3/31/2024 | 7 | -58 | -66 | -54 | N/A |
| 12/31/2023 | 6 | -63 | -73 | -62 | N/A |
| 9/30/2023 | 3 | -82 | -77 | -68 | N/A |
| 6/30/2023 | 3 | -90 | -76 | -68 | N/A |
| 3/31/2023 | 3 | -86 | -69 | -63 | N/A |
| 12/31/2022 | 2 | -87 | -65 | -60 | N/A |
| 9/30/2022 | N/A | -74 | -59 | -56 | N/A |
| 6/30/2022 | N/A | -63 | -52 | -50 | N/A |
| 3/31/2022 | N/A | -69 | -59 | -58 | N/A |
| 12/31/2021 | N/A | -58 | -49 | -48 | N/A |
| 9/30/2021 | N/A | -48 | -41 | -39 | N/A |
| 6/30/2021 | N/A | -47 | -35 | -34 | N/A |
| 3/31/2021 | 0 | -38 | -16 | -15 | N/A |
| 12/31/2020 | 0 | -34 | -15 | -15 | N/A |
| 6/30/2020 | 0 | -30 | -19 | -19 | N/A |
| 3/31/2020 | N/A | -18 | -19 | -19 | N/A |
| 12/31/2019 | N/A | -20 | -17 | -17 | N/A |
| 9/30/2019 | N/A | -39 | -11 | -11 | N/A |
| 6/30/2019 | N/A | -18 | -12 | -12 | N/A |
| 3/31/2019 | N/A | -19 | -12 | -12 | N/A |
| 12/31/2018 | N/A | -18 | -12 | -12 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: OCGN is forecast to remain unprofitable over the next 3 years.
Winst versus markt: OCGN is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: OCGN is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: OCGN's revenue (69.5% per year) is forecast to grow faster than the US market (8.9% per year).
Hoge groei-inkomsten: OCGN's revenue (69.5% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if OCGN's Return on Equity is forecast to be high in 3 years time